Pablo Domizi, PhD, Stanford University, Stanford, CA, talks on using single-cell multiomics to identify patients at risk of antigen escape following CD19-directed CAR-T therapy, highlighting the pros and cons of these approaches. Dr Domizi explains that technologies such as single-cell RNA-sequencing (scRNA-seq) can provide a lot of information but they are very expensive and need to be validated. Whilst these technologies cannot currently be used in clinical practice, they may play a more important role in the future. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
